location: Home > english > ABOUT US > Board of Directors >
Board of Directors
source:admin time:2017-08-31


Luqa was founded in 2010 by a group of passionate healthcare veterans and entrepreneurs who wanted to build a great team and a great business centered on making medicines that would improve the lives of patients.



Chairman and C.E.O. at Luqa Pharmaceuticals

Robert Braithwaite is one of Luqa’s founding members and serves as the company’s C.E.O. since its foundation in 2010. Robert has lived and worked in China since 2005, where he initially built Almirall’s presence in the country, whilst leading efforts to develop presence in key markets like India and Australia and consolidated Almirall’s products as leaders in their therapeutic categories in Japan and Korea. Earlier in career, Robert was also responsible for Central and Eastern Europe, Middle East and Africa.

Before joining Almirall, Robert spent five years at Alcon where he gained a good understanding of the medical devices markets in a financial controlling role. He also managed Alcon’s businesses in Africa and the Middle East.

Robert has a BA (Honours) from the University of Humberside in the UK. Robert is a UK national and resides in Shanghai.



Non-Executive Director

Hugo Peris has been at Luqa since its inception in 2010, where he led Business Development until May 2015. Hugo is a member of Luqa Pharmaceuticals’ Board of Directors since February, 2012.

Hugo Peris has a broad multinational experience in the pharmaceutical industry. Hugo’s career started in marketing at Novartis Australia & New Zealand where he was responsible for various marketing projects. From late 2009 until late 2010, Hugo worked from Chicago for WraSer Pharmaceuticals in the launch of an innovative otolaryngology product in the Midwest. Since January 2013, Hugo serves as a non-executive member of the Board of Directors of Laboratorios Salvat, a privately-held Spanish pharmaceutical company of which he is part of the 4th generation.

In late 2014 Hugo spun out an R&D asset from Laboratorios Salvat to start Loop Therapeutics, Inc., a US ophthalmic pharmaceutical company focused on developing first-in-class products to treat corneal diseases.

Hugo has a degree in International Business and holds a Master’s degree in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra of Barcelona.

Hugo is a Spanish national and resides in San Francisco, CA.



Non-Executive Director

Pierre Véronneau is a member of Luqa Pharmaceuticals board of Directors since 2012. Pierre has an established experience base which stretches across the major markets of the world through his career as a consulting strategist and as a business developer or with the pharmaceutical companies Almirall and DuPont.

At Almirall, he spearheaded the Licensing and M&A strategy of the company up to the end of 2010. Under his serial licensor leadership, a first ever, transformational, Pan-EU license was secured plus several other important deals were signed. Prior to this role, he was the first General Manager of Almirall¹s newly acquired inhalation technology R&D centre in Germany. When joining the company in 2002, he led a small group of talented licensing professionals, closing deals on 4 continents and managing over 60 partnerships.

Pierre joined the pharmaceutical industry when he was recruited by DuPont Pharma Canada in the late 80’s as a sales representative. He served in various roles of increasing responsibility at local and regional levels before holding national sales, business development and operations leadership at the Canadian headquarters in Toronto.

Pierre is a graduate of the Canadian Forces Officer Candidate School program and the Canadian Army Command and Staff College. He also holds a MBA (Executive) from Concordia University in Montréal. Pierre has both Canadian and French nationalities, and currently lives in Spain.